634 related articles for article (PubMed ID: 10850310)
1. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
3. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
4. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
Bhat SA; Czuczman MS
Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
Jourdan E; Richard B
Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
[TBL] [Abstract][Full Text] [Related]
6. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
7. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
Paul F; Rossi JF; Cartron G
Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
[TBL] [Abstract][Full Text] [Related]
9. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
12. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
[TBL] [Abstract][Full Text] [Related]
13. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
Maloney DG; Press OW
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
[TBL] [Abstract][Full Text] [Related]
14. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
16. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
Hainsworth JD
Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
[TBL] [Abstract][Full Text] [Related]
17. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
[TBL] [Abstract][Full Text] [Related]
18. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
Molina A
Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
[TBL] [Abstract][Full Text] [Related]
19. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N
Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187
[No Abstract] [Full Text] [Related]
20. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
